Breakthroughs in hepatitis C virus (HCV) treatment and rising rates of intravenous drug use have led to an increase in the number of organ donors who are HCV antibody-positive but serum nucleic acid test (NAT)-negative. The risk of HCV transmission from the liver grafts of these donors to recipients is unknown. To estimate the incidence of HCV transmission, we prospectively followed 26 consecutive HCV antibody-negative (n 5 25) or NAT-negative (n 5 1) transplant recipients who received a liver graft from donors who were HCV antibody-positive but serum NAT-negative between March 2016 and March 2017. HCV transmission was considered to have occurred if recipients exhibited a positive HCV PCR test by 3 months following transplantation. Drug overdose was listed as the cause of death in 15 (60%) of the donors. One recipient died 18 days after transplantation from primary graft nonfunction and was excluded. Of the remaining 25 recipients, HCV transmission occurred in 4 (16%), at a median follow-up of 11 months, all from donors who died of drug overdose. Three of these patients were treated with direct-acting antiviral therapy, with two achieving a sustained virologic response and one an end-of-treatment response. One patient with HCV transmission died after a complicated postoperative course and did not receive antiviral therapy. Conclusion: In this prospective cohort of non-HCV liver recipients receiving grafts from HCV antibody-positive/NAT-negative donors, the incidence of HCV transmission was 16%, with the highest risk conferred by donors who died of drug overdose; given the availability of safe and highly effective antiviral therapies, use of such organs could be considered to expand the donor pool.
W hile over 14,000 individuals are awaiting liver transplantation in the United States, only 7,841 transplants were performed in 2016 because the demand exceeds the supply of donor organs.
(1) The marked rise in incidence of intravenous drug use and the ready availability of highly successful treatments for hepatitis C virus (HCV) infection have led to an increasing number of potential organ donors who are positive for HCV antibody (seropositive) but nonviremic, as indicated by negative serum nucleic acid testing (NAT). (2) A potential opportunity to expand the donor pool would be through the offering of organs from these individuals, which are otherwise reserved for HCV-infected recipients, to any patient on the transplant waiting list. An HCV antibody-positive/NAT-negative serologic status could be found in individuals who develop spontaneous clearance of the virus (which occurs in 15%-25% of cases (3) (4) (5) ) or who are successfully treated for chronic HCV infection. In addition, this specific combination of serologies could be produced by a false-positive HCV antibody test as the third-generation enzyme-linked immunosorbent assay has a specificity of 92%-100% (6, 7) or by a falsenegative HCV NAT (sensitivity 98%-99% (8) ). Organs from individuals who are HCV antibodypositive/serum NAT-negative generally have not been considered for donation to non-HCV patients and have been discarded if an HCV viremic recipient is not available (9) due to concerns about HCV transmission. In this regard, Suryaprasad et al. (10) reported six potential cases of HCV transmission to non-HCV transplant recipients through nonliver organs obtained from NAT-negative, increased-risk donors. Our understanding of HCV transmission from NAT-negative donors to liver transplant recipients is limited because the use of seropositive liver organs has historically been restricted to recipients who have detectable HCV viremia, irrespective of the viremia status of the donor. Indeed, the literature is limited to two case reports in which transplantation of an organ from an HCVseropositive, nonviremic living donor who had previously achieved a sustained virological response (SVR) to interferon therapy did not result in HCV transmission to the recipient. (11, 12) While HCV transmission from viremic donors is essentially universal, we report on the clinical outcomes and incidence of HCV transmission related to use of HCV antibody-positive/ serum NAT-negative organs for cadaveric liver transplantation.
Participants and Methods

STUDY POPULATION
In 2015, the University of Cincinnati Medical Center began offering non-HCV liver transplant candidates the option of receiving an organ from HCV-seropositive, nonviremic liver donors as a way to decrease waiting times on the transplant list. Non-HCV status of the candidates was defined as either HCV antibody-negative or, in the case of HCV antibody-positive candidates, an undetectable NAT within 6 months prior to transplantation. Transplant candidates were informed that the risk of HCV transmission was unknown but could be as high as 5% based on historical data. Notably, the majority of HCV-seropositive donors meet public health services (PHS) increased-risk criteria for infection transmission and potentially may fall within the "eclipse period" of HCV reinfection during which viremia may not be detectable by current assays. Studies suggest a 0.32% risk of HCV infection transmission within the eclipse period. (13) However, a recent guide from the Disease Transmission Advisory Committee of the Organ Procurement and Transplantation Network (OPTN) estimates the risk of HCV transmission from donors with immediate needle exposure to be as high as 3%. (14) We also considered the conceptual risk of HCV transmission from occult hepatitis C infection (OCI), in which residual HCV genome is present in liver tissue or peripheral blood mononuclear cells after self-induced or treatment-induced clearance of viremia. (15) (16) (17) Informed written consent was obtained in the office setting, and transplant candidate profiles were updated to reflect their eligibility for HCV-seropositive organs. Hercules, CA) was used for all donors, while the methodology for HCV NAT varied. Three different NAT assays were used among the 12 organ procurement organizations. Details of these assays are summarized in Table 1 . (18) (19) (20) Donor liver biopsies were performed at the discretion of the transplant surgeon. No donor organs were obtained from executed prisoners or other institutionalized persons.
DONOR SELECTION
FOLLOW-UP AND OUTCOME MEASURES
All patients received standard immunosuppression posttransplantation, which consisted of tacrolimus, mycophenolate mofetil, and corticosteroids per institutional protocol. Patients with renal insufficiency or who were on hemodialysis in the perioperative period received antithymocyte globulin (rabbit) to suppress the cluster of differentiation 3 count to <25/mm 3 until delayed introduction of tacrolimus by postoperative day 7. Tacrolimus trough levels were maintained between 8 and 12 ng/mL during the first 3 months. In addition to standard posttransplant management, all patients underwent HCV PCR testing (Roche COBAS Ampliprep TNAI/TaqMan 48 RUO Assay; limit of detection 15 IU/mL; Roche Molecular Diagnostics, Pleasanton, CA) 3 months after transplantation or sooner if indicated by a rise in liver chemistries. The 3-month time point was selected as this is the standard interval when oral corticosteroids are discontinued and antiviral therapy is initiated in posttransplant patients with HCV at our institution. Our institutional protocol does allow for earlier intervention with antiviral therapy in the uncommon situation where liver enzymes become markedly elevated and/or the patient develops evidence of fibrosing cholestatic hepatitis C. Recipients who developed HCV viremia were screened for any behavioral risk factors or health care exposure for HCV infection. Antiviral therapy was initiated unless contraindicated. The selection of antiviral therapy was based on provider preference and payer discretion. Data were collected prospectively through August 2017 on consecutive liver transplant recipients who received liver grafts from seropositive, nonviremic donors between March 2016 and March 2017.
MOLECULAR ANALYSIS
For recipients who were HCV antibody-positive prior to liver transplantation and developed posttransplant HCV viremia, molecular testing was performed to characterize pretransplant and posttransplant HCV strains and differentiate between HCV reactivation versus donor transmission. Serum specimens (posttransplant and, if available, stored pretransplant) were obtained from recipients and genotyped. HCV genotyping by nonstructural protein 5B (NS5B) sequencing and phylogenetic analysis of the NS5B region were performed using standard procedures for HCV RNA extraction, RT-PCR using region-specific primers, and Sanger sequencing as has been reported by our group. (21) PCR was performed using the MJ Research Thermocycler PTC-100 machine, and products were submitted to the Massachusetts General Hospital DNA Sequencing Core for direct sequencing. Patient sequences were aligned with references retrieved from the GenBank database (https://www.ncbi.nlm.nih. gov/genbank/?) along with sequences from patients with HCV infection seen in our emergency department using Clustal X v2.1. Additional phylogenetic inference was performed using a Bayesian Markov chain Monte Carlo approach as implemented in the Bayesian Evolutionary Analysis Sampling Trees (BEAST), v1.8.4, program under an uncorrelated lognormal relaxed molecular clock and the general timereversible model with nucleotide site heterogeneity estimated using a gamma distribution. After a 10% burn-in, the phylogenetic tree was visualized in FigTree v1.4.3. Additional NS5B sequences from our previous study (22) were included to compute betweensample genetic distances using the Kimura twoparameter model in Molecular Evolutionary Genetic Analysis (MEGA 7). 
Results
Twenty-six of the 125 liver transplants (20.8%) performed during the study period involved HCVseropositive, nonviremic donors and non-HCV recipients, including 2 patients who received simultaneous liver and kidney transplants and one who received two liver transplants, both from seropositive, nonviremic donors. One recipient died from primary graft nonfunction 18 days after transplantation and was excluded from the analysis (Fig. 1) . Liver histology from this patient's autopsy did not reveal features of viral hepatitis. The median age of the remaining 25 patients was 62 years (range 36-69), and the median Model for EndStage Liver Disease score was 22. Twenty-four were HCV antibody-negative, while one was successfully treated for HCV prior to transplant. The median age for the donors was 41 years. The majority were Caucasian (88%), and most died of a presumed drug overdose (60%). The clinical characteristics of all study participants are summarized in Table 2 . At a median follow-up of 11 months (range 5-18), a total of 4 recipients (16%) developed HCV viremia by 3-month testing. None of these recipients had behavioral risk factors for HCV infection, nor did they have other health care exposures that could have served as a source of acquisition. Only 1 patient met the criteria for molecular testing (case 3). A comparison of the characteristics of the donors who transmitted HCV versus those who did not is summarized in Table 3 . All of the donors who transmitted HCV were 35 years old or younger (100% versus 38%, P 5 0.039). None of the other donor characteristics were significantly correlated with HCV transmission.
All four transmissions were reported to the OPTN and the Diseases Transmission Advisory Committee per OPTN policy 15.5. (23) To date, our center has not been notified of any discordant HCV transmissions from nonliver organs from these donors. The clinical 
CASE 1
A 63-year-old woman with a negative HCV antibody test and liver cirrhosis secondary to primary sclerosing cholangitis received a liver graft from a 27-yearold female donor, categorized as PHS increased-risk, who died from anoxia related to a drug overdose. Donor HCV NAT was performed using Procleix Ultrio assay (Novartis, Gen-Probe, San Diego, CA; Table 1 ) 1 day after hospital admission. A postperfusion liver biopsy was not performed. Three months after transplantation, a quantitative HCV PCR returned >29 million IU/mL (genotype 1a). Treatment with ledipasvir/sofosbuvir plus ribavirin was initiated 33 days after the positive PCR test. SVR was achieved despite early discontinuation of ribavirin 2 weeks into the 12-week treatment course because of adverse effects.
CASE 2
A 61-year-old woman with a negative HCV antibody test underwent liver transplantation for cirrhosis secondary to nonalcoholic steatohepatitis. Her donor was a 32-year-old man, categorized as PHS increasedrisk, who died of anoxia secondary to a heroin overdose. Donor HCV NAT was performed using Procleix Ultrio assay (Novartis, Gen-Probe; Table 1 
CASE 3
A 52-year-old woman with cirrhosis secondary to chronic HCV (genotype 1a) and human immunodeficiency virus coinfection that was complicated by hepatocellular carcinoma underwent liver transplantation. Two and a half years prior to transplant, the patient achieved SVR following a 12-week course of sofosbuvir and daclatasvir. She had remained persistently HCV nonviremic up until the time of transplantation. The donor was a 28-year-old man, categorized as PHS increased-risk, who died from anoxia presumed secondary to a heroin overdose. Donor HCV NAT was performed using the Roche COBAS Ampliscreen assay, v 2.0 (Roche Molecular Diagnostics; Table 1 ), 4 days after hospital admission. A postperfusion liver biopsy showed mild macrovesicular steatosis (20%) and 
CASE 4
A 70-year-old man with a negative HCV antibody test and liver cirrhosis secondary to nonalcoholic steatohepatitis complicated by medically controlled portopulmonary hypertension received an initial liver transplant from an HCV-seronegative donor. His posttransplant course was complicated by primary graft nonfunction, and the patient subsequently underwent retransplantation with an organ from an HCVseropositive, nonviremic donor 60 days after his original operation. The organ donor was a 26-year-old Caucasian man categorized as PHS increased-risk, who died from anoxic injury after being discovered unconscious with drug paraphernalia nearby. Donor HCV NAT was performed using a Roche COBAS Ampliscreen assay, v 2.0 (Roche Molecular Diagnostics; Table 1 ), 1 day after hospital admission. The patient experienced a protracted hospitalization characterized by multidrug-resistant infections and renal failure from acute tubular necrosis necessitating hemodialysis. Three months after the second transplantation, the HCV viral load was >600,000 IU/mL (genotype 3). Infection control breaches were not reported from the hemodialysis center, nor were clusters of HCV infection identified among patients dialyzed at the same center. The patient's condition continued to deteriorate due to difficult-to-control pulmonary hypertension and recurrent lung infections, and he died from complications of pneumonia 9 months after retransplantation. Antiviral therapy was not initiated because of his complicated clinical course and severe debility. The patient did not exhibit any clinical, laboratory, or radiologic evidence of advanced liver disease posttransplantation.
Discussion
Our finding that 4 of 25 (16%; 95% confidence interval 4.5-36) non-HCV liver transplant recipients developed viremia within 3 months of receiving an organ from an HCV-seropositive, nonviremic donor indicates a substantially higher risk of HCV transmission than originally anticipated (estimate 5%; P 5 0.03 using corrected Z statistic). Although isolated cases of liver transplantation using similar donor serologies have been reported, (11, 12) we prospectively assessed the incidence of HCV transmission from such donors. Donor age <35 years was the only clinical predictor of HCV transmission. While our study is not powered to enable us to draw conclusions regarding other factors associated with HCV transmission, certain trends are notable. Donors who transmitted HCV were predominantly male, and all were PHS increased-risk with death due to drug overdose.
Existing literature supports three potential mechanisms of HCV transmission in these situations. As the majority of the donors in our cohort died of drug overdose (15/25) , it is possible that some were within the eclipse period for NAT detection after becoming reinfected with hepatitis C. Supporting literature for eclipse period infection comes from the report of Suryaprasad et al. (10) in which organ transplantation from seronegative, NAT-negative, increased-risk donors resulted in HCV transmission to non-HCV recipients. Although none of the 6 recipients who contracted HCV had received a liver graft, traces of HCV genome were extracted from stored samples of donor splenocytes or lymphatic tissue. In our cohort, eclipse period infection is a likely possibility because all 4 donors in cases that resulted in HCV transmission had recent intravenous drug use. However, a transmission rate of 16% is much higher than expected, even for the donors who had immediate needle exposure. (14) Furthermore, during the same time period that the study was conducted, 28 other non-HCV liver transplant recipients at our center received organs from PHS increased-risk but HCV-seronegative donors, and none developed HCV viremia (study cohort HCV transmission in 4 of 25 versus nonstudy, increased-risk donor HCV transmission in 0 of 28, P 5 0.03 by chi-squared analysis). Another possible contributing mechanism to HCV transmission is the phenomenon of transient low-level viremia, below the limit of detection for current assays, which occurs during the early phase of acute HCV infection when the innate and cellular immune responses are attempting to clear the virus. (5, 24) Alternatively, the presence of OCI in the donor tissue could potentially lead to HCV transmission. Estimates regarding the prevalence of OCI are highly variableranging from 0% to 95%-based on study population and methodology, (25, 26) and the clinical significance is unclear as spontaneous relapse of viremia, including in immunocompromised patients following solid organ transplant, appears to be uncommon (estimated 1%-2% after successful treatment with interferon-based regimens). (15) Evidence in support of OCI includes reports of spontaneous reactivation of successfully treated HCV following chemotherapy or other immune suppression, (27) (28) (29) (30) although such occurrences are uncommon. Whitcomb et al. (31) examined 65 post-SVR liver biopsies from patients with recurrent HCV after liver transplantation and found that 69% had histologic features of active HCV infection, with the majority demonstrating similar or worsening interval fibrosis scores. Notably, only one out of 32 liver biopsies tested was positive for HCV RNA in that study. Elmasry et al. (32) demonstrated presence of HCV RNA in liver tissue from 5 liver transplant recipients with recurrent HCV infection who had achieved SVR after treatment with direct-acting antiviral agents but had persistently elevated liver chemistries. Interestingly, histologic features from one postperfusion liver biopsy (case 2) in our cohort were consistent with chronic HCV infection.
Historically, the use of HCV-seropositive organs for liver transplantation has been reserved for candidates with active HCV viremia at the time of transplant, although it is worth noting that, while HCV-positive transplant candidates are defined as those with viremia, the definition of an HCV-positive donor has been exclusively based on seropositivity. The OPTN did not require HCV NAT for all HCV-seropositive donors until December 2014. (23, 33) However, even with the availability of NAT results, the common practice of labeling HCV-positive donors based solely on antibody testing persists. Recent consensus guidelines by the American Society of Transplantation regarding the use of HCV viremic donors in solid organ transplantation emphasize the importance of distinguishing HCV-seropositive/NAT-positive (viremic) donors from those who are seropositive/NAT-negative (nonviremic), (2) yet scant data are available regarding the outcome of non-HCV liver transplant recipients who receive organs from HCV-seropositive (viremic or nonviremic) donors. (11, 12) Our findings demonstrate that transplanting liver grafts from nonviremic donors, with recent intravenous drug use, into non-HCV recipients carries a nontrivial 16% risk of HCV transmission. Although, the consensus guidelines suggest minimal risk of HCV transmission from seropositive/ NAT-negative liver grafts, (2) our experience highlights the fact that other donor factors, such as PHS risk status, recent history of intravenous drug use and the timing of NAT in donors significantly modify the risk of transmission. This study also highlights that one-time HCV NAT of donors has limited predictive value with regard to HCV transmission to liver transplant recipients and that other donor characteristics such as age, gender, increased-risk behavior, and cause of death may also need to be taken into consideration.
There are notable limitations to our report. We were unable to perform HCV genomic analysis on donor tissue to evaluate for OCI versus eclipse period transmission, thus limiting our ability to explain the exact mechanism of HCV transmission. Furthermore, 3 of the 4 recipients in our cohort who developed hepatitis C posttransplant were not tested for HCV RNA prior to transplant, raising the possibility that some of these individuals might have been seronegative but viremic. However, this seems highly unlikely given that rates of viremia in seronegative patients are under 1% and usually represent acute HCV infection.
(2) All of the recipients in our cohort had well-established etiologies of chronic liver disease, and the likelihood of an acute HCV infection going unnoticed in a patient being closely monitored on a transplant waiting list appears remote.
Demand for liver organs in the United States has always exceeded supply, and the present wait-list mortality of approximately 20% is primarily driven by limited organ availability. (34) In recent years, the number of deceased donor liver transplants has increased by 20%, (1) primarily due to rising rates of death from drug overdose. There is a high prevalence of HCV seropositivity in intravenous drug users, (35) with as many as one-third being nonviremic. (2) Use of organs from these donors provides a unique opportunity to expand the donor pool. Additionally, the recent availability of direct-acting antivirals has dramatically improved the management and outcome of chronic HCV infections, and these agents have been shown to be highly effective and safe in the posttransplant setting. (36) (37) (38) (39) In this cohort, 3 out of 4 patients who contracted HCV from donor organs were successfully treated with directacting antiviral-based regimens. We did not experience any difficulty in obtaining approvals for antiviral therapy from insurance carriers. However, if usage of NAT-negative organs becomes a widespread clinical practice, specific protocols with prior authorization from insurance companies could be considered given the higher than expected rate of HCV transmission. A recent report demonstrating an 88% SVR rate in a small cohort of liver transplantation recipients with active viremia at the time of liver transplantation who received 4 weeks of ledipasvir/sofosbuvir in the immediate postoperative period (40) suggests that it may be possible to employ an abbreviated course of antiviral therapy as a prophylaxis measure while using organs from donors with high risk of HCV transmission.
In conclusion, we found a 16% incidence of HCV transmission following transplantation of liver allografts from seropositive/nonviremic donors with recent intravenous drug use to non-HCV recipients. The underlying mechanisms of HCV transmission require further investigation by examining the donor liver tissue using HCV genomic analysis. Due to the availability of highly effective and safe treatments for hepatitis C, the use of such organs could significantly expand the donor pool.
